← All trials
NCT06203431
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 11, 2023
- Primary completion
- Apr 30, 2024
- Completion date
- Jun 30, 2024
- First posted
- Jan 12, 2024
- Last posted
- Jan 12, 2024
- Enrollment
- 270
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- FosunLead sponsor
- Sichuan UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.